Victory Capital Management Inc. boosted its position in shares of Stryker Corp. (NYSE:SYK) by 2.7% during the second quarter, Holdings Channel reports. The fund owned 12,935 shares of the medical technology company’s stock after buying an additional 341 shares during the period. Victory Capital Management Inc.’s holdings in Stryker Corp. were worth $1,550,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. LSV Asset Management purchased a new position in shares of Stryker Corp. during the second quarter worth $107,000. Global X Management Co. LLC boosted its position in shares of Stryker Corp. by 235.8% in the second quarter. Global X Management Co. LLC now owns 994 shares of the medical technology company’s stock worth $119,000 after buying an additional 698 shares during the last quarter. Carroll Financial Associates Inc. boosted its position in shares of Stryker Corp. by 78.0% in the second quarter. Carroll Financial Associates Inc. now owns 1,086 shares of the medical technology company’s stock worth $130,000 after buying an additional 476 shares during the last quarter. CWM LLC purchased a new position in shares of Stryker Corp. during the second quarter worth $150,000. Finally, Everett Harris & Co. CA purchased a new position in shares of Stryker Corp. during the second quarter worth $201,000. Hedge funds and other institutional investors own 75.48% of the company’s stock.

Stryker Corp. (NYSE:SYK) traded up 0.35% during midday trading on Tuesday, reaching $114.82. The company’s stock had a trading volume of 588,442 shares. Stryker Corp. has a 52-week low of $86.68 and a 52-week high of $123.55. The stock has a market capitalization of $42.98 billion, a price-to-earnings ratio of 27.07 and a beta of 0.71. The firm has a 50-day moving average price of $114.41 and a 200 day moving average price of $112.71.

Stryker Corp. (NYSE:SYK) last released its earnings results on Thursday, July 21st. The medical technology company reported $1.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.37 by $0.02. Stryker Corp. had a net margin of 15.33% and a return on equity of 23.61%. The business earned $2.84 billion during the quarter, compared to analysts’ expectations of $2.79 billion. Equities research analysts predict that Stryker Corp. will post $5.76 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 31st. Investors of record on Friday, September 30th will be given a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 1.33%. The ex-dividend date of this dividend is Wednesday, September 28th. Stryker Corp.’s dividend payout ratio (DPR) is presently 35.85%.

A number of brokerages have commented on SYK. Canaccord Genuity restated a “buy” rating and set a $130.00 price objective on shares of Stryker Corp. in a research note on Sunday, July 24th. Zacks Investment Research upgraded Stryker Corp. from a “hold” rating to a “buy” rating and set a $130.00 price objective on the stock in a research note on Tuesday, June 21st. Guggenheim began coverage on Stryker Corp. in a research note on Wednesday, June 8th. They set a “buy” rating and a $134.00 price objective on the stock. Brean Capital restated a “buy” rating and set a $125.00 price objective (up previously from $121.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Finally, Jefferies Group restated a “hold” rating and set a $120.00 price objective (up previously from $113.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. Stryker Corp. currently has a consensus rating of “Hold” and a consensus price target of $114.91.

In related news, Director Ronda E. Stryker sold 18,000 shares of the stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $117.34, for a total value of $2,112,120.00. Following the completion of the transaction, the director now owns 193,142 shares of the company’s stock, valued at $22,663,282.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 12,000 shares of the stock in a transaction dated Friday, September 16th. The stock was sold at an average price of $112.85, for a total transaction of $1,354,200.00. Following the completion of the transaction, the director now directly owns 193,142 shares of the company’s stock, valued at approximately $21,796,074.70. The disclosure for this sale can be found here. 7.80% of the stock is currently owned by corporate insiders.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corp. (NYSE:SYK).

Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.